A retrospective longitudinal cohort study of 3,637 adults with moderate-to-severe depression reports that higher subjective psychedelic intensity at 2 weeks of sublingual ketamine treatment was associated with greater reductions in depression severity at 4 weeks.
The US Drug Enforcement Administration has proposed 2027 aggregate production quotas for Schedule I and II controlled substances and an assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine and phenylpropanolamine. Written comments are due by December 10, 2026, under Docket No. DEA-1730P, after which the Administrator will publish a final order.
A newly registered trial, PATCH, will evaluate whether psilocybin can increase the effectiveness of amblyopia therapy in adults with amblyopia. The study will assess whether ingesting psilocybin, a naturally occurring psychoactive compound, can enhance treatment outcomes in this population.
Australia's Therapeutic Goods Administration has published interim decisions on proposed amendments to the Poisons Standard from ACMS #48, Joint ACMS-ACCS #42 and ACCS #41, and invited comment by 4 December 2026. The notice covers interim decisions only; the amendments are not final.
NYU Langone Health has registered a double-blind, parallel-design, placebo-controlled, two-centre randomised controlled trial of single-dose psilocybin-assisted psychotherapy in 100 outpatients with early-stage breast cancer. The trial is designed to evaluate efficacy and psychological mechanisms for fear of cancer recurrence (FCR), anxiety and depression distress and quality of life, comparing a single 25mg oral dose of psilocybin with a single 5mg oral dose as an active placebo, both delivered with a psychotherapy platform.
Why it matters: The registry record sets out a two-centre design with an active placebo, so readers can see how the trial plans to separate psilocybin from expectancy in fear of cancer recurrence.
30 OctFri
Friday
Europe PMC: new psychedelic research papersAI score5555
A randomised, double-blind, placebo-controlled pilot trial in 20 participants with treatment-resistant major depressive disorder found no statistically significant between-group difference in anhedonia at the primary week 1 endpoint, with a DARS change difference of 11.2 (95% CI, -1.0 to 23.3; p = 0.073) for psilocybin 25 mg versus 1 mg, both given with psychological support.
A newly registered open-label trial will use PET imaging to study cerebral metabolism in healthy adults after a single dose of ayahuasca. The registry entry lists no sample size, dosing details or results.
A double-blind, randomised, placebo-controlled trial registered on ClinicalTrials.gov assigned 28 healthy volunteers to four single-dose groups of seven: ayahuasca 0.5 mL/kg, 1.0 mL/kg, 1.5 mL/kg or placebo. The study examined effects on personality. No results are reported in the registration entry.
The US Food and Drug Administration has issued a request for information on approaches it is considering for the design of early-phase clinical trials of ibogaine drug products, and is seeking public comment.
Why it matters: The request sets out the protocol questions the agency wants answered, including a starting dose cap, so researchers and sponsors can see what evidence the FDA expects before early-phase ibogaine trials proceed.
19 SepSat
Saturday
Europe PMC: new psychedelic research papersAI score5252
A review examines the relationship between classic psychedelics such as LSD, psilocybin and DMT and suicidality, proposing a theoretical double-edged sword model. The authors report that several deaths followed non-medical psychedelic use in unsafe contexts, with unclear suicidal intent, and that rare cases of increased suicidal ideation and behaviours in clinical settings showed no significant differences from placebo groups or established causality.
A systematic review of 62 studies, only 2 in humans, reports that psychedelic administration appears to enhance associative learning in animals across conditioning paradigms, though findings were not consistent. The authors write that direct evidence of enhanced associative learning in humans remains limited, while human studies show altered cognitive flexibility and learning-related processes.
Why it matters: The review separates animal evidence of enhanced associative learning from the limited human data, a distinction that matters for claims about the post-acute window used in psychedelic-assisted psychotherapy.
The TGA has published its interim decisions on proposed amendments to the Poisons Standard considered at ACMS #47 and Joint ACMS-ACCS #40, and invites comment. The closing date for submissions is 10 July 2026. The notice is a summary only and does not list the substances or amendments covered.
Why it matters: The notice marks the interim stage of scheduling, so anyone with an interest in the proposed Poisons Standard amendments has until 10 July 2026 to comment before a final decision.
The TGA has extended the closing date for comment on its interim decision on a proposed amendment to the Poisons Standard concerning psilocybine, from ACMS #47, to 31 July 2026. The interim decision follows the June 2025 advisory committee meeting.
The TGA has published its notice of final decisions on whether to amend the Poisons Standard, following the Advisory Committee on Chemicals Scheduling (ACCS) #40 and the Joint Advisory Committee on Medicines Scheduling and Advisory Committee on Chemicals Scheduling (Joint ACMS-ACCS) #39. The publication is issued under regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990. The feed supplied only a summary, so the specific substances and outcomes are not stated here.
Why it matters: The notice is the formal record of which scheduling proposals were accepted or rejected, so companies and prescribers can check whether a compound's legal status changed.
28 JanWed
Wednesday
Advisory Council on the Misuse of Drugs (UK)AI score5858
The Advisory Council on the Misuse of Drugs has advised the UK government that ketamine should remain a class B controlled substance, after the government asked it in January 2025 to review the prevalence and harms of ketamine misuse.
The Advisory Council on the Misuse of Drugs has published an updated review of the use and harms of ketamine, following a commission from the then Minister for Policing, Fire and Crime Prevention in January 2025. The report reviews prevalence and harms of ketamine and its analogues in the UK, describes legitimate uses including treatment and research, covers emerging health harms such as hepatobiliary toxicity, and describes supply and trafficking.
Why it matters: The review was commissioned to advise on ketamine's classification, so its findings on prevalence, hepatobiliary toxicity and supply could shape how the UK schedules the drug and its analogues.
The TGA has published interim decisions on proposed amendments to the Poisons Standard arising from the Advisory Committee on Chemicals Scheduling (ACCS) #40 and the Joint Advisory Committee on Medicines Scheduling and Advisory Committee on Chemicals Scheduling (Joint ACMS-ACCS) #39. The notice invites comment, with a closing date of 23 January 2026. The feed gave no further detail on which substances or schedules the interim decisions cover.